VERACYTE, INC.

Veracyte, Inc. (Nasdaq: VCYT) is a global diagnostics company that develops and commercializes molecular diagnostic tests to guide cancer care decisions across the patient journey from diagnosis through treatment monitoring. The company operates through a dual-model structure, offering laboratory developed tests through CLIA-certified laboratories in the United States and in vitro diagnostic tests distributed internationally through hospitals and laboratories.

The company's core portfolio includes Decipher Prostate for prostate cancer risk assessment, Afirma for thyroid cancer evaluation, Decipher Bladder for bladder cancer prognosis, and Prosigna for breast cancer risk stratification. Veracyte also offers the Percepta Nasal Swab test for lung cancer risk assessment in patients with suspicious lung nodules. In 2024, the company acquired C2i Genomics to add minimal residual disease capabilities, positioning it to serve patients across the broader cancer care continuum with its TrueMRD platform.

Revenue is derived from multiple sources including Medicare fee-for-service, which represented 34 percent of testing revenue in 2025, Medicare Advantage at 18 percent, private commercial payers at 47 percent, and Medicaid at one percent. The company maintains CLIA-certified laboratories in South San Francisco and San Diego, California, and Austin, Texas, supported by cytopathology expertise.

Veracyte's competitive advantages center on its proprietary Veracyte Diagnostics Platform, which combines whole-transcriptome analysis, artificial intelligence capabilities, and extensive evidence generation to drive clinical adoption and reimbursement. The company has published over 115 peer-reviewed studies supporting Decipher Prostate and maintains strong guideline inclusion across its test portfolio, including recognition in NCCN and ASCO guidelines.

The company holds registered trademarks for Veracyte, Afirma, Percepta, Envisia, Prosigna, Lymphmark, Decipher, GRID, C2i, and C2i Genomics, with a pending trademark for TrueMRD. Veracyte operates globally with particular focus on European expansion through its IVD offerings and partnerships with sequencing platform manufacturers including Illumina. The company's website is www.veracyte.com.